Massive genomic analyses have underscored the diversity of chronic lymphocytic leukaemia (CLL) between patients. Genetic heterogeneity of tumour clones within a patient may fuel tumour evolution. Several recurrently deregulated intracellular pathways are candidates for targeted therapies that are very promising and are dramatically changing clinical patients' perspectives. In this review we present an overview of the genetic and epigenetic features of CLL and their clinical and biological implications.
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western World and is mainly a disease of the elderly, with nearly twice the incidence in men as in women. CLL is characterized by clonal proliferation and the accumulation of mature CD5 + CD23 + B lymphocytes in the bone marrow, peripheral blood and lymphoid tissues (Zenz et al, 2010a) . The vast majority of CLL cases are thought to arise from a precursor state, known as monoclonal B-cell lymphocytosis (MBL) (Ghia & Caligaris-Cappio, 2012) , which differs from CLL essentially by the concentration of circulating B-lymphocytes. CLL is biologically and clinically a very heterogeneous disease, where some patients never require therapy and some patients display an aggressive course with poor response to therapy and death within months. The advent of next generation sequencing (NGS) has helped to elucidate the underlying biological mechanisms and activated pathways implicated in the development of CLL (Fig 1) . Following many excellent reviews [including, but not limited to: Fabbri and Dalla-Favera (2016) ; Guieze and Wu (2015) ; Roos-Weil et al (2016) ; Strefford (2015) ], we will focus on recent data on CLL physiopathology as well present potential clinical and biological implications.
Genomics
In comparison with other hematological malignancies or solid tumours, CLL is characterized by a relatively stable genome. The average mutational burden in CLL of less than 1 mutation per megabase of genomic DNA is low compared with solid tumours (such as lung cancer and melanoma that carry on average 10 mutations per megabase) . The slow evolution pace of CLL enables identification of the evolutionary steps that are elusive in other tumour types, because of sampling difficulties or faster dynamics. The comprehensive mutational landscape of CLL has confirmed the clues from early cytogenetic analyses, and showed marked inter-and intra-patient genetic heterogeneity. Hence, only the analyses of large numbers of patients allow evaluation of the frequencies and clinical correlations of genomic abnormalities.
Cytogenetics and copy number alterations
Cytogenetic aberrations have been associated with prognosis in CLL (Table I) . A landmark study of 325, mainly untreated, CLL patients identified five prognostic categories using fluorescence in situ hybridization (FISH), based on 17p deletion, 11q deletion, trisomy 12, normal FISH and 13q deletion as the sole abnormality (Dohner et al, 2000) . The 13q14 deletion correlates with better prognosis if isolated. However these patients can be divided into two types, type I which encompasses MIR15A/MIR16-1 and DLEU2 but not the retinoblastoma (RB1) gene; and the larger type II deletion that includes RB1 and would be associated with a more aggressive disease (Ouillette et al, 2011) . The 11q deletions are identified in~6-20% of CLL patients at diagnosis and are associated with poor outcome. Deletion of the long arm of chromosome 11 is usually a mono-allelic deletion encompassing the tumour-suppressor gene ATM (ataxia telangiectasia-mutated). The other ATM copy is targeted by somatic mutations (Rose-Zerilli et al, 2011) . The 11q deletion can also involve the BIRC3 gene at 11q22.2 (see infra) . CLL patients with 17p deletions (encompassing the TP53 locus at 17p13) display a poor outcome with a rapid progression and short survival (Greipp et al, 2013; Stilgenbauer et al, 2014) . Most of these cases show inactivation of both TP53 copies, but monoallelic inactivation of TP53 is also an adverse prognostic marker (Zenz et al, 2010b) . Trisomy 12 is identified in about 20% of CLL and correlates with intermediate outcome. Trisomy 12 is mainly considered as driver mutation occurring early in the disease course. Associations between the presence of trisomy 12 with driver mutations in genes, such as NOTCH1 and BIRC3, were identified (Del Giudice et al, 2012; Landau et al, 2015) . The mechanisms by which trisomy 12 contribute to CLL pathogenesis are not known. Genomic aberrations, such as deletions of 6q, 8p, 14q and 15q, amplification of 8q and gain of 2p, trisomy 18 and 19, are found in CLL (Edelmann et al, 2012) . However, these aberrations occur with a low incidence Genes and biological processes affected by frequent CLL mutations. Red stars indicate genes and pathways recurrently mutated in CLL including NOTCH1, NFjB, RNA processing, chromatin remodeling and DNA repair, synthesis and damage response. The green star indicates the single nucleotide polymorphism (SNP) (rs539846 C>A) in the BCL2-modifying factor (BMF) enhancer at 15q15. This SNP disrupts a conserved RELA transcription factor-binding site and alters RELA-mediated enhancer activity, resulting in reduced expression of the pro-apoptotic BMF. The black star indicates recurrent somatic intergenic mutations identified in a PAX5 enhancer within the chromosome 9p13 region. These mutations were shown to significantly associate with PAX5 downregulation. and lack independent prognostic value. Chromosome 2p gain is however associated with advance disease and treatment resistance (Chapiro et al, 2010) . A complex karyotype (defined as composed of 3 or more abnormalities) has been associated with an unfavourable prognosis, short time to treatment and poor response to treatment Herling et al, 2016; Yu et al, 2016) . Almost 20% of cases with no aberration detected by the standard FISH panels ("normal" FISH) were reported to carry complex karyotypes (Rigolin et al, 2012) . Recently, it was reported that complex karyotype is an independent powerful predictor of poor outcome of Ibrutinib-based therapy Thompson et al, 2015) . In addition, in a prospective clinical trial, Herling et al (2016) reported that complex karyotype aberrations is an independent prognostic factor for survival after front-line therapy and that patients with both complex karyotypes and TP53 aberrations present a particularly short survival.
Gene mutations
The introduction of NGS has led to an massive exponential increase in the knowledge of the molecular underpinnings of CLL and highlighted further the heterogeneity of this disease. Up to a dozen whole CLL genomes and more than 1300 whole CLL exomes have been investigated. These studies confirmed a marked genetic heterogeneity of CLL. Most genes are mutated in less than 5% of the samples and virtually all mutations can be either clonal (i.e. early acquired and present in all tumour cells) or subclonal (i.e. present only in a fraction of the cells). The mutations may however converge to the deregulation of a handful of biological processes including NOTCH1 signalling, NFjB pathway, B-cell receptor (BCR) and Toll-like receptor (TLR) signalling, RNA splicing, ribosomal processing, DNA damage repair and cell cycle control (Tables II and III , Fig 1) . These studies also drew attention to natural and treatment-induced evolutionarily processes.
Notch signalling
The proto-oncogene NOTCH1 is mutated in approximately 10% of patients when they initially require treatment but this increases to more than 20% in relapse and up to 40% in Richter transformation (Rossi et al, 2012a; Oscier et al, 2013) . NOTCH1 mutations are essentially truncating mutations within exon 34 that result in the loss of the PEST domain. This domain is responsible for the instability of the wild type protein and its loss has been shown to stabilize the mutant proteins and therefore enhance NOTCH signalling. A frameshift deletion [c.7544_7545delCT (p.P2514 fs)] within exon 34 has been reported to account for up to 90% of NOTCH1 mutations in CLL. Non-coding mutations lying in the 3 0 UTR region of NOTCH1 cause aberrant splicing events with a cryptic exonic splice donor site and results in a deletion of the last 158 coding bases of exon 34 and, similarly, the loss of the PEST domain . The most frequent recurrent non-coding mutation causing aberrant Larrayoz et al, 2017) . NOTCH1 noncoding mutations in the UK CLL4 trial (489 patients) were found to be mutually exclusive to NOTCH1 coding variants and were not identified in cases with mutations of TP53, BIRC3, MYD88 (L265P), NFKBIE and RPS15 mutations (Larrayoz et al, 2017) . Arruga et al (2016) engineered the MEC1 cell line and showed that NOTCH1 signalling may regulate growth and homing of the cells. PEST domain mutations increase NOTCH1 signalling, STAT3 phosphorylation, CCR7 expression and reduce the MAPK/STAT negative control protein phosphatase DUSP22. STAT3 phosphorylation, high levels of CCR7 and low DUSP22 expression appear to be associated with NOTCH1 mutant in primary samples (Arruga et al, 2016) . The signalling couple, CCR7 and CCL19 has been associated with central nervous system localization on NOTCH1-mutated T-ALL samples (Buonamici et al, 2009) . NOTCH1 mutations are enriched in CLL harbouring trisomy 12 (Balatti et al, 2012; Puente et al, 2015) and are significantly more common in CLL with unmutated IGHV genes, when they are associated with increased levels and signalling of surface IgM (D'Avola et al, 2016) . Mutations in the FBXW7 and MED12 genes might also deregulate the NOTCH1 signalling pathway in CLL. FBXW7 encodes an E3 ubiquitin ligase that regulates the stability of several proteins, such as NOTCH1, MYC, JUN, MTOR and MCL1 by targeting them for ubiquitination and degradation (Welcker & Clurman, 2008) . Inactivating mutations of FBXW7 are observed in 2Á5% of CLL cases (Jeromin et al, 2014) . MED12, the mediator complex subunit 12 gene, encodes a subunit of the Mediator complex, a conserved eukaryotic transcriptional regulator of RNA polymerase II (Fryer et al, 2004) . MED12, MED13, CDK8 and Cyclin C comprise a four-subunit kinase module that exists in association with a 26-subunit Mediator core complex, which regulates many transcriptional programs important for development and/or tumourigenesis. CDK8 represses NOTCH signalling-driven transcription by promoting turnover of the NOTCH intracellular domain (ICD) (Fryer et al, 2004) . Indeed, CDK8-mediated phosphorylation of the PEST domain of NOTCH ICD is required to target this protein for ubiquitination and subsequent degradation by the E3 ligase FBW7 (Fryer et al, 2004) . MED12 was implicated in tumourigenesis when highly specific exon 2 mutations were identified in many tumours. Mutations were observed in 5% of the CLL patients and were suggested to associate with well-known poor prognosis markers in CLL (Damm et al, 2014; Kampjarvi et al, 2015) . Mutations disrupt the interaction between MED12 and the Cyclin C-CDK8 complex and lead to a diminished Mediator-associated CDK kinase activity (Kampjarvi et al, 2015) . A conditional knockout mouse model showed that MED12 is an essential regulator of haematopoietic stem/ progenitor cell (HSPC) biology through its implication in promoter-enhancer interactions (Aranda-Orgilles et al, 2016) . The absence of MED12 in HSPC results in release of Cyclin C-CDK8 from the Mediator core complex and the loss of p300, PolII, and H3K27ac at enhancer regions of key HSPC genes, resulting in HSPC loss (Aranda-Orgilles et al, 2016) .
In vitro data showed that inhibition of NOTCH1 signalling with the c-secretase inhibitor (GSI), PF-03084014, triggers apoptosis and reduces proliferation in NOTCH1-mutant CLL cells (Rosati et al, 2013; Lopez-Guerra et al, 2015) . GSI was also shown to enhance the cytotoxic effect of fludarabine in NOTCH1-mutated CLL cases even in the presence of a protective microenvironment .
Mutations affecting the RNA processing pathway
The SF3B1 gene, encoding SF3B1, shows somatic missense mutations in 10-20% of the CLL cases. SF3B1 is a component of the spliceosome that is involved in the binding of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP) to the branch point of 3 0 intronic splicing sites. Mutations lie within hotspots (codons 662, 666, 700, 704, 742) , with codon 700 harbouring 50% of the mutations, and affect the C-terminal HEAT-repeat region of the protein. SF3B1 mutations promote the use of alternative branch point based on their greater (with respect to the regular ones) complementarity to the U2 snRNA, leading to the inclusion of 3 0 intronic sequences in the mature RNA (Darman et al, 2015; Alsafadi et al, 2016; Kesarwani et al, 2016; Saez et al, 2016) . It was suggested that SF3B1 mutations increase NOTCH signalling via alternative splicing of a negative regulator of NOTCH signalling, DVL2 . Mutations in other genes involved in RNA splicing and processing including SRSF1 (previously termed SFRS1), SRSF7 (previously termed SFRS7), U2AF2 (Quesada et al, 2011) , DDX3X (Wang et al, 2011) NXF1 and RANBP2 have also been described. As SF3B1 mutations are associated with progressive/refractory disease, targeting SF3B1 may be of therapeutic interest in CLL, as suggested for SRSF2 mutants in myeloid malignancies . Drugs targeting the U2 snRNP spliceosome are available, including pladienolide, spliceostatin A and sudemycin (Kaida et al, 2007; Xargay-Torrent et al, 2015; Larrayoz et al, 2016) . Indeed, preclinical investigation of spliceosome inhibitors in CLL cells showed encouraging results especially in combination with B cell lymphoma 2 (BCL2) inhibitors and ibrutinib .
XPO1, which encodes the nuclear exporter Exportin-1, is mutated in CLL. Mutations are observed predominantly in CLL with unmutated IGHV (~5%). However, the prognostic relevance of the mutations still remains to be determined. XPO1 is a member of the karyopherin-b superfamily of nuclear transporters and plays a central role in nuclear export through complexes with Ran-GTP and cargo proteins containing a leucine-rich nuclear export sequence, including tumour suppressor proteins, cell cycle inhibitors and growth receptor proteins, such as TP53 and STAT3 and inhibitor of NFjB (IjB) (Lapalombella et al, 2012) . The most recurrent XPO1 mutations are missense mutations in exon 15 at codon 571 (p.E571K). This mutation lies in the hydrophobic groove of XPO1 that binds to the leucine-rich nuclear export signal (NES) of cargo proteins. The human XPO1 gene is located on chromosome 2 (2p15). The gain of the short arm of chromosome 2 (2p) is a recurrent aberration in CLL (Chapiro et al, 2010) and was shown to result in XPO1 overexpression and drug resistance in CLL (Cosson et al, 2017) .
XPO1 is a therapeutic target in CLL. Selinexor (KPT-330, or the more recent KPT-8602) is a selective inhibitor of nuclear export (SINE) that forms a reversible covalent bond with XPO1 and inhibits its function (Hing et al, 2016) . Selinexor synergizes with ibrutinib ex vivo and in the El-TCL1 mouse model of CLL (Hing et al, 2015) . Furthermore, selinexor has been shown to disrupt BCR signalling by suppressing BTK gene expression, inhibiting phosphorylation of AKT and ERK and to be effective against the escape from ibrutinib of the BTK C481S mutation. Indeed, selinexor enforces nuclear retention of IjB, leading to inhibition of NFjB in CLL cells and subsequent BTK down modulation (Hing et al, 2015) .
Implication of the BCR and TLR pathways and NFjB signalling
MYD88 is an adaptor protein for interleukin-1 (IL1) and TLR signalling. MYD88 associates with the TLR TIR domain and recruits IRAK4, which then induces the phosphorylation of the related IRAK2/IRAK1 kinases. Phosphorylated IRAK1/ 2 promotes TRAF6 recruitment, which subsequently ubiquitinates and activates TAK1. TAK1 activation induces the phosphorylation of the IKK complex. IKK-mediated phosphorylation of IjB promotes its ubiquitination and degradation, ultimately driving NFjB activation, thus promoting cell survival and proliferation (Ngo et al, 2011; Mansouri et al, 2016a) . Mutations in MYD88 are observed at low frequencies (2-3%) in CLL. The predominant MYD88 mutation is a missense mutation, p.L265P, which leads to downstream activation of the NFjB and JAK pathways (Ngo et al, 2011) . MYD88 mutations are almost exclusively associated with mutated IGHV CLL and thus with a favourable prognosis. They may be linked to distinct clinicobiological profiles (Rossi et al, 2012b; Xu et al, 2013; Cortese et al, 2014; Jeromin et al, 2014; Puente et al, 2015) . Several studies reported that MYD88 mutations had no impact on time to first treatment (TTFT) or overall survival (OS) Jeromin et al, 2014; Baliakas et al, 2015) , however, a study by Martinez-Trillos et al (2014) reported that MYD88 mutations were enriched in young CLL patients and associated with longer time to next treatment (TTNT) and OS (MartinezTrillos et al, 2014) .
The RAS-MAPK pathway lies downstream of the B-cell receptor signalling (Damm et al, 2014; Herling et al, 2016) , and mutations in genes involved in this pathway, such as KRAS (2-6%) and BRAF (3-10%), have been reported in CLL. KRAS mutations correlated with a poor response to chemoimmunotherapy (Herling et al, 2016) . Mutated BRAF was identified as independent prognostic drivers for shorter TTFT . Exploring the vulnerability of BRAF/KRAS-mutant CLL to existing targeted therapies for MEK, BRAF or ERK inhibitors might offer treatment options to be investigated in such cases.
NFΚB pathway
The NFΚB pathway is essential for B-cell development and survival and is activated by many B-cell oncogenes, including MYD88 mutants (Cuni et al, 2004; Hewamana et al, 2008; Herishanu et al, 2011; Zhang et al, 2017) .
The NFKB inhibitor I-kappa-B-epsilon (NFKBIE) gene encodes a negative regulator of NFjB signalling, which traps the REL protein in the cytoplasm. It has a specific role in the late retro-control of B cell response to external stimuli, including signalling through the BCR and TLRs (Alves et al, 2014) . NFKBIE is inactivated by a recurrent 4-bp truncating mutation in addition to rare point mutations in 5-10% of CLL (Damm et al, 2014; Mansouri et al, 2015; Ljungstrom et al, 2016; and several B cell lymphomas (2-23%) (Mansouri et al, , 2016b Morin et al, 2016) . NFKBIE mutations are enriched among advanced stage CLL and associated with poor-prognostic markers, suggesting that they might be involved in disease progression Mansouri et al, 2016b; . In CLL, the NFKBIE deletion was associated with significantly shorter TTFT similar to IGHV-unmutated or 17p-deleted patients. High frequencies of NFKBIE deletions (23%) are observed among primary mediastinal B-cell lymphoma patients and were shown to be an independent poor prognosis factor in multivariate analysis (Mansouri et al, 2016b) .
The BIRC3 (Baculoviral IAP Repeat Containing 3) gene encodes a member of the inhibitor of apoptosis protein (IAP) family that negatively regulates the non-canonical NFjB pathway. BIRC3 cooperates with TRAF3 and TRAF2, in the negative regulation of MAP3K14, the central activator of noncanonical NFjB signalling. In CLL, inactivating mutations of BIRC3 lead to the activation of NFjB signalling (Rossi et al, 2012b) . The BIRC3 locus is located close to the ATM locus on 11q (Rossi et al, 2012b; Cortese et al, 2014) . Rare mutations in TRAF2 and TRAF3 were also described in CLL. BIRC3 mutations are strongly associated with unmutated IGHV CLL, ATM mutations 11q deletion and shorter TTFT (Rose-Zerilli et al, 2011; Rossi et al, 2013; Baliakas et al, 2015) . The frequency of BIRC3 mutations is approximately 3-8% at the time of diagnosis but mutations may emerge over time (Rose-Zerilli et al, 2011; Rossi et al, 2012b; Cortese et al, 2014; Baliakas et al, 2015; Puente et al, 2015) . Amongst fludarabine-refractory cases the frequency may rise to 24% and is exclusive to TP53 abnormalities (Rossi et al, 2012b; Cortese et al, 2014) . Although BIRC3 mutations may be a strong predictor of fludarabine-refractoriness (Rossi et al, 2012b) , their low frequencies in early-stage CLL limit their usefulness at diagnosis (Cortese et al, 2014) . BIRC3 mutations were also described in splenic marginal zone lymphoma and mantle cell lymphoma (MCL) and recent findings in MCL suggest that BIRC3 mutations may be associated with refractoriness to the BTK inhibitor ibrutinib (Rossi et al, 2012b; Cortese et al, 2014; Rahal et al, 2014) .
NFjB signalling can be blocked by different types of inhibitors, including IKK inhibitors, proteasome inhibitors that block IjB degradation, inhibitors of the nuclear translocation of NFjB subunits and suppressors of NFjB DNA binding (Mansouri et al, 2016a; Zhang et al, 2017) . In CLL, the preclinical activity of several direct and indirect NFjB pathway inhibitors has been reported, including the IKK inhibitors BAY-117082 (Pickering et al, 2007) , IMD-0354 (Kanduri et al, 2011) and BMS-345541 (Lopez-Guerra et al, 2009) and proteasome inhibitors, bortezomib (Faderl et al, 2006) , and curcumin (Everett et al, 2007) . Targeting by these inhibitors of NFjB leads to apoptosis of CLL cells in vitro. Moreover, directly inhibiting NFjB drugs, such as PBS-1086 [Pan-REL proteins inhibitor (Fabre et al, 2012) ] and IT-901 [inhibitor of the NFjB subunit c-Rel (Shono et al, 2016) ] have shown promising pre-clinical results in haematological malignancies but have not yet been approved for clinical use. However, to date, none of these inhibitors is currently tested in a clinical trial, primarily due to their toxicity, with the exception of bortezomib, for which a single-agent phase II study of 19 fludarabine-refractory CLL patients revealed no objective response.
Cell cycle, apoptosis and DNA damage and synthesis ATM is a tumour suppressor gene encoding a cell cycle checkpoint kinase linking DNA-damage to cell cycle and DNA repair but also controlling many other cellular functions, including metabolism and chromatin structure. Clonal ATM mutations are associated with a shorter progression-free survival (PFS) and OS after first line treatment (Skowronska et al, 2012; Nadeu et al, 2016) , but this is apparently not the case for subclonal ATM mutations. Targeted treatments of ATMdefective CLL are investigated in preclinical studies (Knittel et al, 2015; Kwok et al, 2016) . ATM-deficient cells rely on alternate DNA damage response (DDR) pathways for DNA double strand breaks repair. Indeed poly(ADP-ribose) polymerase 1 (PARP-1) and protein kinase DNA-PKcs inhibitors might display selective toxicity against ATM-defective cells and present a high potential for the treatment of ATM-mutant CLL cells (Knittel et al, 2015) . Furthermore, a recent study reported that AZD6738, a selective inhibitor of ATR (ATM and Rad3-related protein) led to synthetic lethality in primary CLL with ATM or TP53 deficiency in vitro and in patientderived xenografts model where it showed synergism with chemotherapy (Kwok et al, 2016) . Inhibition of ATR signalling by AZD6738 in CLL cells led to an accumulation of unrepaired DNA damage, which was carried through into mitosis because of defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe.
The TP53 tumour suppressor gene lies at 17p and is inactivated through deletion and mutations in CLL (Dohner et al, 2000; Zenz et al, 2010b) . More than 95% of the identified CLL TP53 mutations are found in exon 5-8, encoding the DNA binding domain (Rossi et al, 2009 ). Both 17p deletion and TP53 mutations are associated with poor survival and resistance to chemotherapy (Rossi et al, 2009) . Another mechanism that can inactivate TP53 is the overexpression of MDM2, a TP53-specific ubiquitin ligase that mediates its degradation. TP53-inactivated CLL cells with TP53 mutations, deletions or MDM2 overexpression show lower levels of MIR34A than CLL cells with no TP53 mutations or 17p deletion and a more aggressive course of the disease (Zenz et al, 2009; Asslaber et al, 2010) . MIR34A has a number of pro-tumour activities, including participation in the regulation of TP53 activity. Activated TP53 induces MIR34A expression and MIR34A activates TP53 by inhibiting SIRT1, an NAD-dependent deacetylase involved in (Fig 2) .
SAMHD1 encodes the sterile a motif and histidine-aspartic domain (HD) containing protein 1. It is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase that regulates the cellular pool of dNTPs required for DNA synthesis and maintenance (Clifford et al, 2014) . SAMHD1 loss of function is predicted to result in increased dNTP cellular levels, DNA synthesis and cell cycle progression leading to cell proliferation and survival. It was shown that 3-5% of CLL patients have acquired mutations in SAMHD1 at diagnosis (Clifford et al, 2014) . However, SAMHD1 mutation frequency is increased in relapsed/refractory CLL (9-11%) without associated increase of other poor risk factors, such as 11q deletion or unmutated IGHV (Clifford et al, 2014; Amin et al, 2016) . Two independent studies associated SAMHD1 mutations with resistance to standard CLL therapies (Clifford et al, 2014; Amin et al, 2016) . Indeed, standard treatments may select pre-existing clones carrying SAMHD1 mutations (Amin et al, 2016) . Recent works suggest that SAMHD1 mediates cytarabine (Ara-C) resistance by decreasing intracellular Ara-CTP, the therapeutically active Ara-C metabolite (Schneider et al, 2016; Herold et al, 2017) . Conversely, SAMHD1 inactivation increases sensitivity to Ara-C and, to a lesser extent, fludarabine (Schneider et al, 2016) . Whether a heterozygous SAMHD1 mutation in CLL generates sufficient differential sensitivity of tumour cells to fludarabine remains to be determined.
POT1 is involved in telomere maintenance. Mutations in POT1 lead to telomere dysfunction and, in turn, disruption of DNA maintenance, control of chromatin structure and splicing regulation (Colla et al, 2015) . Telomere dysfunction drives aberrant haematopoietic differentiation and myelodysplastic syndrome. POT1 mutations are present in 3Á5% of CLL cases, in the clinically aggressive CLL subtypes (Ramsay et al, 2013) . POT1 mutations were also reported to occur at higher frequency in Richter syndrome as compared to CLL (Fabbri et al, 2013) . Germline POT1 mutations and mutations in other genes of the telomere sheltering complex are associated with familial CLL . In a prospective clinical trial, Herling et al (2016) , recently reported that complex karyotypes and POT1 mutations (8Á1% of patients in this trial) are significant prognostic factors for an unfavourable survival, independently of IGHV mutation status, Binet stage, and serum b-2-microglobulin. Given the prevalence of POT1 mutations in the most aggressive form of CLL, monitoring of POT1 mutation is warranted.
Ribosomal Protein (RP) gene mutations have been identified in many cancers. including endometrial cancer, T-cell acute lymphoblastic leukaemia, colorectal carcinomas, high grade glioma and CLL (Rao et al, 2012; De Keersmaecker et al, 2013; Lawrence et al, 2014; Landau et al, 2015) . RPS15 is recurrently mutated in CLL (~5%). All mutations within RPS15 lie within a hotspot region in exon 4 and target a 7 amino-acid evolutionary-conserved region. RPS15 mutations are associated with a shorter PFS, an aggressive, relapsed form of CLL and resistance to fludarabine-based chemotherapy (Landau et al, 2015; Ljungstrom et al, 2016) . Wildtype RPS15 is shown to bind to MDM2 and inhibit its E3 ubiquitin ligase activity, leading to lack of TP53 degradation, upregulation of TP53 target genes, G2 arrest and cell apoptosis (Daftuar et al, 2013) . RPS15 mutations are frequently associated with TP53 mutations. Mutant RPS15 p.G132A experimentally increased TP53 degradation through increased ubiquitination, as compared with wild-type RPS15 Yu et al, 2016) .
Transcription factors
Mutations in genes encoding transcription factor controlling B-cell biology such as EGR2, IRF4 and IKZF3 are observed in Fig 2. Alteration in cell cycle, apoptosis and DNA damage response pathway could be targeted pharmacologically. Various DNA damage activates ATM, ATR or DNA-PK kinases that activate TP53 to trigger apoptosis or stop cellular division to allow DNA repair. These kinases also phosphorylate and inactivate MDM2, a TP53-specific E3 ubiquitin ligase, further stabilizing TP53. In CLL, recurrent genetic lesions inactivate TP53 or ATM. Overexpression of MDM2, a TP53-specific ubiquitin ligase also impairs TP53 function. RPS15 may act as an inhibitor MDM2 E3 ligase activity. RPS15 mutations may lead to defective TP53 stability and increased degradation. MIR34A, a direct transcriptional target of TP53, participates in the regulation of TP53 activity. In CLL, aberrations along the TP53 axis cause MIR34A downregulation, which is associated with resistant disease. Synthetic lethality could be exploited in CLL patients that harbour mutations in DNA repair pathway genes. Specific nodes in the pathway that are therapeutically actionable are indicated.
~2% of CLL (Havelange et al, 2011; Damm et al, 2014; Landau et al, 2015) . The majority of EGR2 mutations identified in CLL are heterozygous missense mutations that are localized in the DNA-binding sites of the three zinc-finger domains and predominantly affect the codons E356, H384 and D411 (Damm et al, 2014) . EGR2 mutations are significantly enriched in patients with aggressive disease and, in particular, treatment refractory cases (Damm et al, 2014; Ljungstrom et al, 2016; Young et al, 2017) . Heterozygous missense mutations (L116R/P) in the DNA-binding domain of the IRF4 gene are identified in 2% of CLL cases, with the majority of these cases also carrying trisomy 12 (Havelange et al, 2011; Shukla et al, 2013) . Deletion of Irf4 in mice leads to development of CLL-like leukaemia (Shukla et al, 2013) . In CLL, IKZF3 is affected by a recurrent missense mutation p.L162R substitution that resides in the second zinc finger domain (Landau et al, 2015) .
Recurrent somatic intergenic mutations were identified in genomic regions within chromosome 9p13 and the region was identified as a distant PAX5 transcription regulatory element . These mutations were significantly associated with a reduction in transcription of the B-cell-specific transcription factor PAX5 in model cell lines and primary CLL samples. Initially suggested to associate only with 13q deletion this noncoding "PAX5 mutation" was shown to be associated with MYD88, ATM, NOTCH1, SF3B1 and ZMYM3 mutations in CLL (Rose-Zerilli et al, 2016). Similar mutations are also observed in diffuse large B-cell lymphomas (DLBCL; 29%), follicular lymphomas (23%) and mantle-cell lymphomas (5%). PAX5 is known to control the identity of B lymphocytes throughout B cell development by activating B-cell commitment genes while concomitantly repressing non-B-lineage genes (Cobaleda et al, 2007) . PAX5 is initially expressed at pro-B cell stage and is maintained until plasma cell differentiation occurs. The loss of Pax5 results in a block at the pro-B cell stage in adult mice. PAX5 has also been implicated in human B cell malignancies, through somatic mutations and chromosomal translocations in B-cell lymphomas and B-ALL (Poppe et al, 2005; Mullighan et al, 2007) .
Epigenetic and chromatin modification
Genes encoding proteins involved in the control of chromatin modification (including CHD2, ASXL1, KMT2D (MLL2), SETD2, ZMYM3, ARID1A and HIST1H1B) are recurrently mutated at low frequency (Landau et al, 2015; Puente et al, 2015; Parker et al, 2016) . Somatic mutations of the chromatin remodeler CHD2 gene have been found in 5Á3% of CLL and 7% in MBL. Most mutations are truncating or target functional domains that impact CHD2 association with active chromatin and lead to altered nuclear distributions . SETD2 is a histone methyltransferase responsible for the trimethylation of lysine 36 on histone 3 (H3K36me3), an epigenetic mark involved in transcriptional elongation . In human cells, SETD2 interacts with RNA pol II and plays a role in alternative splicing and DNA repair (Jha & Strahl, 2014; Pfister et al, 2014) . A new role for SETD2 in the methylation of K40 of a-tubulin was identified and SETD2 loss results in a dysfunctional mitotic spindle and abnormalities in cytokinesis leading to genomic instability . In CLL, somatic SETD2 mutations occur in up to 4% of patients, affect one copy with no evidence of inactivation of the other (Landau et al, 2015; Puente et al, 2015; Parker et al, 2016) . SETD2 mutations are identified as early loss-offunction events in CLL and are linked to aggressive disease (Parker et al, 2016) . Histone H1 functions as an internucleosome linker facilitating folding and packaging of DNA into higher order chromatin structure (Laybourn & Kadonaga, 1991) . Human cells contain five canonical, replication-dependent somatic histone H1 subtypes H1.1 to H1.5 encoded by HIST1H1A, C, D, E and B genes, respectively. H1 variants are differentially expressed during development and cellular differentiation, and regulate specific gene expression, threedimensional genome organization and chromatin organization (Izzo et al, 2013; Geeven et al, 2015) . In CLL, mutations in H1 are primarily missense mutations spread over the proteins (Landau et al, 2015) . Mutations in H1 genes are also observed in follicular lymphoma Okosun et al, 2014) . Molecular analysis of one of these mutants, H1S102F, showed reduced capacity to associate with chromatin and to bind DNMT3B Okosun et al, 2014) . It is however not known whether these histone H1 mutations would affect chromatin structure and transcriptional regulation.
Beside mutations targeting chromatin organizers, genomewide analyses have been used to compare CLL chromatin structure and DNA methylation with normal B-cells (Kulis et al, 2012; Landau et al, 2014; Queiros et al, 2015; Rendeiro et al, 2016) . Three CLL groups have been identified with respect to the level of differentiation associated DNA methylation maturity that are termed low-, intermediate-and high-programmed . These 3 groups had different IGHV mutational status, IGHV usage and diverse prognostic impact. Low-programmed samples have been associated with unmutated IGHV, ZAP70 hypomethylation and expression, and poor prognosis. IGHVmutated CLL belonged to the high-programmed DNA methylation subtype and the intermediate-programmed cases were enriched in CLL using IGHV3-21. Furthermore, DNA methylation maturation status inversely associates with surface IgM levels and BCR signalling capacity in mutated CLL (D'Avola et al, 2016) . Surface IgM levels and signalling were higher in unmutated CLL than in mutated CLL and correlated with disease progression. Aberrant methylation leading to dysregulated expression of CLL-associated microRNAs and long non-coding RNAs has been reported in CLL (Garding et al, 2013) . The two long non-coding RNAs, Deleted in leukaemia 1 (DLEU1) and 2 (DLEU2), a bona fide tumour suppressor locus in lymphoid malignancies that map to the 13q14 region, were found upregulated in CLL through DNAdemethylation at their promotor. This demethylation correlated with transcriptional deregulation of a cluster of neighbouring protein-coding tumour suppressor genes and the two microRNAs MIR15A and MIR16-1, which may act as regulators of NFjB activity (Garding et al, 2013) .
Somatic mutations and clinical impact
Clonal deletions and mutations of TP53 are known to be poor prognosis factors, with drug resistance to the standard therapy fludarabine-cyclophosphamide-rituximab (FCR). Subclonal TP53 mutations have been shown to similarly confer poor prognosis (Nadeu et al, 2016; Rasi et al, 2016) . NGS approaches are mandatory given the extremely low mutation levels, undetectable by classical analyses impact prognosis (Hallek et al, 2008; Pospisilova et al, 2012; Rossi et al, 2014; Malcikova et al, 2015; Amin et al, 2016; Edelmann et al, 2016; Nadeu et al, 2016; Rasi et al, 2016) , and argue for a need to repeat TP53 inactivation analysis prior to any subsequent line of therapy (Hallek et al, 2008; Pospisilova et al, 2012) . The BTK inhibitor, ibrutinib, the phosphatidylinositol 3-kinase delta inhibitor, idelalisib and the BCL2 inhibitor, venetoclax, represent therapeutic options (Roberts et al, 2016) . ATM mutations in the absence of 11q deletion are infrequent compared to with 11q deletion; however, they have a significant impact on TTFT (Rose-Zerilli et al, 2011; Nadeu et al, 2016) . In contrast to subclonal ATM mutations, clonal mutations are associated with a shorter PFS and OS after first line treatment (Skowronska et al, 2012; Nadeu et al, 2016) .
Among mutated genes in CLL, the NOTCH1, SF3B1 and BIRC3 genes have attracted attention due to their frequency. Alterations of NOTCH1, SF3B1 and BIRC3 were significantly correlated with survival in consecutive series from several independent institutions (Sportoletti et al, 2010; Fabbri et al, 2011; Quesada et al, 2011; Wang et al, 2011; Puente et al, 2015; Nadeu et al, 2016; Rasi et al, 2016) , including relapsed/ refractory CLL . NOTCH1-mutated CLL are associated with low CD20 levels (Pozzo et al, 2016) and do not benefit from the addition of an anti-CD20 monoclonal antibody to the fludarabine and cyclophosphamide combination. Indeed, treatment of NOTCH1-mutated CLL with FCR shows no improvement in PFS or OS compared to treatment with only FC . SF3B1 status determines response to FCR and mutated patients had a shortened PFS . NOTCH1, SF3B1 and BIRC3 mutations are enriched in TP53 wild-type fludarabine refractory patients (Messina et al, 2014) .
Patients with subclonal mutations of NOTCH1 have a significantly shorter TTFT, while subclonal SF3B1 mutations do not appear to influence disease outcome (Nadeu et al, 2016) . Rasi et al (2016) suggest thresholds for prognosis impact: mutations should be represented in at least 25%, 35% and 1% of the alleles of NOTCH1, SF3B1 and BIRC3, respectively, to have the maximum impact on CLL OS, in contrast with subclonal TP53 mutations for which relevance to the outcome of CLL is independent of their abundance.
The prognostic relevance of many gene mutations is still unclear because their frequencies are too low to reach statistical significance. For example, the independent prognosis value of NFKBIE, MYD88, SAMHD1, XPO1, RPS15, POT1, BRAF, EGR2 mutations need to be confirmed in CLL.
Resistance to targeted therapy
In normal B cells, activation of the BCR receptor triggers an intracellular signalling cascade that includes protein tyrosine kinase LYN, Spleen tyrosine kinase (SYK), BTK, phospholipase Cc2 (PLCc2) and phosphoinositide 3-kinase (PI3K). In CLL, BCR signalling is abnormal and poor prognosis is associated with active BCR signalling and tumour B-cells are highly dependent on BCR-signalling (Herishanu et al, 2011; Damm et al, 2014; Puente et al, 2015) . BCR signalling inhibitors, such as ibrutinib (BTK inhibitor) or idelalisib (PI3K delta inhibitor), have demonstrated clinical activity in relapsed/refractory CLL patients as a single agent or combined to rituximab (Byrd et al, 2013; Furman et al, 2014; Gopal et al, 2014; Farooqui et al, 2015) . Despite the impressive efficacy of these drugs, some patients fail to respond and some develop resistance. Mutations in BTK that change the binding site of the inhibitor, such as Cys481Ser, were recurrently found in ibrutinib-resistant patients (Woyach et al, 2014) . Mutations in the SH2 domain of BTK (T316A) were also reported to be responsible for ibrutinib resistance (Sharma et al, 2016) . Other mutations allowing escape from treatment include a gain of function mutation activating PLCc2, a downstream target of BTK that may exist prior to ibrutinib treatment (Burger et al, 2016) . Mutations in PLCG2 (encoding PLCc2) were identified as non-synonymous mutations occurring in exon 19 (P664S and R665W), exon 20 (cS707Y) and exon 24 (L845F) or a 6-nucleotide deletion in exon 20 (c.2120-2125del), leading to the deletion of S707 and A708 (Ahn et al, 2017) . Mechanisms of resistance to idelalisib have not yet been described in CLL; however, preclinical studies primarily from other cancers suggest that upregulation and gain-of-function mutations of other members of the PI3K pathway (PIK3CA or PIK3CB) and MYC amplification could be possible mechanisms of resistance (Cheah & Fowler, 2016) .
The BCL2 oncogene has been shown to be important for CLL cell development and its overexpression is associated with resistance to chemotherapy. Venetoclax is a selective inhibitor of BCL2 and was recently approved by the US Food and Drug Administration as monotherapy for patients with CLL and 17p deletion. It acts similarly to the BH3-only proteins, which are natural antagonists of BCL2 and of prosurvival related proteins. The first clinical trial in patients with relapsed/refractory CLL revealed impressive results (Roberts et al, 2016) . In this trial, 20% of patients achieved complete remission, including 5% achieving minimal residual disease negativity, as judged by flow cytometry analyses (Roberts et al, 2016) , which is generally not observed using PI3K and BTK inhibitors. Limited data is available regarding the mechanisms of resistance to venetoclax but could be mediated by the upregulation of MCL1, BCL-XL (also termed BCL2L11) or AKT constitutive activation driven by survival signals from microenvironment (Choudhary et al, 2015; Oppermann et al, 2016) . In vitro studies and screening of kinase inhibitors identified dasatinib, ibrutinib, sunitiniband and idelalisib that can be combined with venetoclax to overcome resistance (Oppermann et al, 2016) . Indeed, ibrutinib causes downregulation of MCL1 and BCL-XL (Cervantes-Gomez et al, 2015).
Clonal evolution
Both inter-and intra-patient genomic heterogeneity is very high in CLL. Indeed, the subclone ratio may also differ in a patient with respect to body localization. Intra tumour heterogeneity fuels evolution and disease relapse, allowing response to selective pressures from tumour microenvironment and chemotherapy or targeted therapies Malcikova et al, 2015) . Longitudinal genetic investigation of sequential samples (from pretreatment and relapse after FCR treatment), revealed three types of CLL evolution: (i) no evolution, (ii) linear evolution, characterized by the maintenance of a founder clone with successive acquisition of new mutations, and (iii) branched evolution, defined as parallel evolution of competitive clones. This latter group is associated with increased speed of disease evolution and poor prognosis, whereas linear evolution seems to be associated with the Richter transformation of CLL into DLBCL (Schuh et al, 2012; Chigrinova et al, 2013; Fabbri et al, 2013; Ouillette et al, 2013; Wang et al, 2014; Landau et al, 2015; Ojha et al, 2015; RoseZerilli et al, 2016) . The application of NGS to anatomically distinct specimens from the same CLL patient contributed to the dissection of clonal evolution. Several studies evidenced clonal heterogeneity between different anatomical sites (e.g. lymph node and peripheral blood) and showed that mutations in the lymph nodes expand in the peripheral blood at relapse following positive selection by therapy (Schuh et al, 2012; Del Giudice et al, 2016; . Using NGS and copy number alteration/aberration analysis of leukaemic cells isolated simultaneously from peripheral blood and lymph node of nine CLL patients, Del Giudice et al (2016) identified specific subclonal mutations in each compartment and cases with clonal driver aberrations within lymph nodes (SF3B1 mutation, BIRC3 deletion, del8p and gain 2p) that were only detected in the blood as small circulating subclones. Several groups have reported on acquired ibrutinib resistance and BTK and PLCG2 mutations in patients with CLL who progressed on ibrutinib therapy (Woyach et al, 2014; Burger et al, 2016; Ahn et al, 2017) . Subclonal mutations in BTK and PLCG2 may arise concurrently in different cells or on different alleles. For example, a male patient (with a single X-chromosome BTK allele), showed three separate subclones carrying individual mutations in the Cys481 codon and two distinct PLCG2-mutated subclones (Ahn et al, 2017) . In a recent study investigating ibrutinib resistance, one of the patient relapsed with a non-B-cell sarcoma carrying the CLL mutations and IGH rearrangement but lacking B-cell markers, underscoring the plasticity of the tumour cells (Burger et al, 2016) .
Genetic predisposition to CLL
CLL appears to show a relatively common familial aggregation and epidemiological studies are in support of a genetic susceptibility to CLL. The incidence of CLL varies across geographic areas, being higher in Europe and people of European descent and lower in South and East Asia and sub-Saharan Africa (Yuille et al, 2000; Goldin et al, 2004; Cerhan & Slager, 2015) . Multiple independent loci influencing risk have been identified. Such studies may identify novel genes, pathways and mechanisms to better understand and treat CLL.
Genome-wide association study analyses have identified around 30 single nucleotide polymorphisms (SNPs) from 31 loci for CLL including 2q13 (BCL2L11), 2q37.1 (SP140), 6p25.3 (IRF4), 4q25 (LEF1), 5p15.33 (TERT), 7q31.33 (POT1), 8q24.21 (MYC), 11q24.1, 15q15.1 (BMF), 16q24.1 (IRF8) and 18q21.33 (BCL2) (Cerhan & Slager, 2015; Berndt et al, 2016) . Several of the identified SNPs lie near or within genes that are mutated in CLL (e.g., SAMHD1, POT1, TERT, IRF4) or whose products may participate in pathways deregulated in CLL (e.g., TERT); studies of these predisposition alleles may help to understand sporadic CLL development and identify other pathways involved in CLL development.
The functional and epigenetic analysis of the CLL susceptibility locus located in an enhancer at 15q15.1 was identified to target the expression of the pro-apoptotic BCL2-modifying factor (BMF), a BH3-only member of the BCL2-related protein family (Kandaswamy et al, 2016) . Fine-mapping of the 15q15.1 CLL risk locus identified the SNP rs539846 C>A as the lead SNP. Chromatin structure analyses of lymphoblastoid cell lines (LCLs) and primary CLL cells suggest that rs539846 lies within an active enhancer in the third intron of BMF. It was further shown to disrupt a conserved RELA transcription factor-binding site, leading to a reduced expression of BMF (Kandaswamy et al, 2016) . BMF interacts and inhibits the anti-apoptotic members of the BCL2 family. BMF was involved in the control of the generation of autoreactive B cells and Bmf-knockout mice exhibit B-cell hyperplasia and develop age-dependent B cell-restricted lymphadenopathy (Labi et al, 2008; Hayakawa et al, 2016) .
Cell of origin
CLL has been considered to originate from mature B lymphocytes (Seifert et al, 2012; . Transcriptomic approaches pinpointed to a post-germinal center B cell while unmutated CLL instead was suggested to derive from an unmutated CD5 + B-cell subset (Seifert et al, 2012) . In recent years, several studies have presented evidence suggesting that the earliest genetic and epigenetic events in CLL development might occur in the haematopoietic stem progenitor cells (HSPCs). Recently, Damm et al (2014) demonstrated that some CLL driver mutations (e.g. SF3B1 or NOTCH1) are shared between the mature CLL clone, HSPCs and the haematopoietic progenitor populations, demonstrating that those mutations occur in a progenitor able to undergo both lymphoid and myeloid differentiation (Damm et al, 2014) . Moreover, HSPCs from CLL patients were suggested to exhibit abnormal B-cell differentiation in a xenograft model, indicating self-renewing HSPC as the cell of origin for CLL (Kikushige et al, 2011) . NGS enables deeper analysis of the IGHV status and the presence of multiple IGHV rearrangements was evidenced in the same patient in up to 5-24% of CLL cases (Langerak et al, 2011; Kriangkum et al, 2015; Stamatopoulos et al, 2016) . This could be possible by a lack of allelic exclusion and the presence of two productive rearrangements or may correspond to the presence of multiple leukaemic subclones. The identification of multiple clones with different IGHV rearrangements in CLL suggest that leukaemia-initiating events might occur prior to IGHV rearrangement in an unrearranged early B-cell progenitor (Kriangkum et al, 2015; Stamatopoulos et al, 2016) .
Conclusions
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